71 related articles for article (PubMed ID: 20205099)
41. [The effect of levothyroxine suppression therapy for benign thyroid nodules on bone metabolism in premenopausal women].
Akinci B; Demir T; Cömlekçi A; Karaoğlu O; Seçil M; Yeşil S
Kulak Burun Bogaz Ihtis Derg; 2008; 18(4):232-7. PubMed ID: 19052491
[TBL] [Abstract][Full Text] [Related]
42. Bone metabolism in patients with differentiated thyroid carcinoma receiving suppressive levothyroxine treatment.
Mikosch P; Obermayer-Pietsch B; Jost R; Jauk B; Gallowitsch HJ; Kresnik E; Leb G; Lind P
Thyroid; 2003 Apr; 13(4):347-56. PubMed ID: 12804103
[TBL] [Abstract][Full Text] [Related]
43. Bone turnover markers in patients with differentiated thyroid carcinoma after levothyroxine withdrawal.
Gao YC; Gu Q; Liu QP; Ge WL; Lu HK
Clin Lab; 2010; 56(3-4):87-93. PubMed ID: 20476639
[TBL] [Abstract][Full Text] [Related]
44. Biochemical markers of bone metabolism in mild ankylosing spondylitis and their relationship with bone mineral density and vertebral fractures.
Mitra D; Elvins DM; Collins AJ
J Rheumatol; 1999 Oct; 26(10):2201-4. PubMed ID: 10529140
[TBL] [Abstract][Full Text] [Related]
45. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis.
Garnero P; Sornay-Rendu E; Chapuy MC; Delmas PD
J Bone Miner Res; 1996 Mar; 11(3):337-49. PubMed ID: 8852944
[TBL] [Abstract][Full Text] [Related]
46. [Evaluation of bone mineral density and selected metabolic markers of bone in boys with constitutional delay of growth and puberty].
Krupa B
Ann Acad Med Stetin; 2000; 46():165-76. PubMed ID: 11712302
[TBL] [Abstract][Full Text] [Related]
47. Treatment of juvenile goitre with levothyroxine, iodide or a combination of both: the value of ultrasound grey-scale analysis.
Einenkel D; Bauch KH; Benker G
Acta Endocrinol (Copenh); 1992 Oct; 127(4):301-6. PubMed ID: 1449041
[TBL] [Abstract][Full Text] [Related]
48. Cross-sectional study shows that impaired bone mineral status and metabolism are found in nonmosaic triple X syndrome.
Stagi S; Di Tommaso M; Scalini P; Sandini E; Masoni F; Chiarelli F; Verrotti A; Giglio S; Romano S; de Martino M
Acta Paediatr; 2017 Apr; 106(4):619-626. PubMed ID: 28090675
[TBL] [Abstract][Full Text] [Related]
49. [The assessment of selected markers of bone tissue metabolism and bone mineral density in girls with resulting from forced weight reduction].
Krawczyk J; Głyda A; Warenik-Szymankiewicz A; Meczakalski B
Ginekol Pol; 1999 May; 70(5):401-6. PubMed ID: 10462991
[TBL] [Abstract][Full Text] [Related]
50. [Influence of genetic factors on the result of therapy for diffuse euthyroid goiter].
Galkina NV; Troshina EA; Mazurina NV
Probl Endokrinol (Mosk); 2009 Feb; 55(1):14-18. PubMed ID: 31569872
[TBL] [Abstract][Full Text] [Related]
51. Effect of L-thyroxine on bone mass.
Weissel M; Kerö D; Woloszczuk W
Ann Intern Med; 1991 Feb; 114(4):339-40. PubMed ID: 1987885
[No Abstract] [Full Text] [Related]
52. Bone minerals and levothyroxine.
Egsmose C; Hegedüs L; Lund B; Hansen JE
Lancet; 1992 Aug; 340(8816):436. PubMed ID: 1353595
[No Abstract] [Full Text] [Related]
53. Bone minerals and levothyroxine.
Walker JD; Mariash CN; Oppenheimer JH
Lancet; 1992 Aug; 340(8816):436-7. PubMed ID: 1353596
[No Abstract] [Full Text] [Related]
54. Bone minerals and levothyroxine.
Wenzel KW
Lancet; 1992 Aug; 340(8816):435-6. PubMed ID: 1353594
[No Abstract] [Full Text] [Related]
55. [Basal metabolism of a group of subjects consisting mostly of children living in the commune of Regalbuto suffering from goiter].
VASTA M; BUSCEMI R
Endocrinol Sci Cost; 1960 Dec; 26():348-52. PubMed ID: 13780455
[No Abstract] [Full Text] [Related]
56. [Bone struma].
HEILMANN P
Zentralbl Allg Pathol; 1950 Jan; 86(1):17-9. PubMed ID: 15406282
[No Abstract] [Full Text] [Related]
57. [Diffuse euthyroid goiter: epidemiology, etiology and pathogenesis, a role of genetic factors in its development, and treatment].
Galklna NV; Mazurina NV; Troshina YA
Probl Endokrinol (Mosk); 2006 Aug; 52(4):49-56. PubMed ID: 31627646
[No Abstract] [Full Text] [Related]
58. Bone mineral density and bone microarchitecture after long-term suppressive levothyroxine treatment of differentiated thyroid carcinoma in young adult patients.
Mendonça Monteiro de Barros G; Madeira M; Vieira Neto L; de Paula Paranhos Neto F; Carvalho Mendonça LM; Corrêa Barbosa Lima I; Corbo R; Fleiuss Farias ML
J Bone Miner Metab; 2016 Jul; 34(4):417-21. PubMed ID: 26056020
[TBL] [Abstract][Full Text] [Related]
59. Bone mineral density and metabolism in levothyroxine-treated adolescent girls with euthyroid diffuse goiter.
Matusik P; Małecka-Tendera E; Franek E; Januszek-Trzciakowska A
Endokrynol Pol; 2010; 61(1):14-9. PubMed ID: 20205099
[TBL] [Abstract][Full Text] [Related]
60. [The bone mineral density and the markers of the osseous circle in children with non-toxic parenchymatous or nodular goiter long-time treated with L-thyroxine].
Zak T; Golenko A; B Wasikowa R; Jedrzejuk D; Noczyńska A
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2005; 11(1):13-7. PubMed ID: 15850533
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
